Lancet: SCB-2019, another potential candidate for COVID-19!

As of February 2, 2021, there were more than 100 million new coronavirus infections worldwide, and more than 2.24 million people died from new coronavirus infections.
countries around the world are working hard to develop new coronavirus vaccines, some of which are now on the market.
SCB-2019 is a vaccine candidate for a protein sub-base that contains a stable triumber form of ratchet (S)-protein (S-Trimer) and two different adjutens.
the results of the SCB-2019 dosage and adulent rationality study in this paper.
the study, a randomized, double-blind, placebo-controlled Phase 1 trial, recruited healthy adult volunteers from two age groups: young: 18-54 years old;
subjects were randomly assigned two doses of the vaccine (3 sg, 9 sg or 30 sg) or a placebo (0.9% NaCl) for a 21-day interval.
SCB-2019 in the form of additives (S-Trimer protein only), as well as AS03 or CpG/Alum.
the original reaction 7 days after vaccination.
tested SCB-2019 with IgG antibodies, ACE2 competitive blocking IgG antibodies, and neutral antibodies through ELISA.
19 June - 23 September 2020, a total of 151 volunteers were recruited, three of whom withdrew for some reason.
148 volunteers were followed for at least four weeks after being given two doses of the vaccine (or placebo) and were included in the analysis.
resistance to adverse event vaccines was good, with only two cases of level 3 adverse events (9?g AS03-admissive group and 9?g CpG/Alum-admissive group).
the most common local adverse reactions were mild injectable partial pain, most commonly seen in AS03-Admission-SCB-2019 (44-69%), while the rates of local adverse reactions in CpG/Alum-Alum-Adulent-SCB-2019 and non-admissive were 6-44% and 3-13%, respectively.
After the first dose of the vaccine, young people were more likely to have systemic adverse reactions (38 percent vs. 17 percent) than older people, but after the second dose, the rates increased to similar levels in both age groups (34 percent vs. 30 percent of the elderly).
least immune response (three serum transformations in 50 days) of SCB-2019, which binds antibodies without adulations.
, however, a fixed dose of ASB-CPG/Alum admissible SCB-2019 can induce binding antibodies and medium antibody high titration serum conversion in both age groups (36 days, the average titration of anti-SCB-2019 IgG antibodies is 1567-4452 (AS03) and 174-2440 (CpGlum/Alum) respectively).
antibody titrations in all AS03 dose groups and CpG/Alum 30 sg groups were higher than serum sample titration during the recovery period in COVID-19 patients.
two adage SCB-2019 preparations caused T-assisted cells 1 to be biased in favor of CD4 plus T cells.
and antibody all in all, the SCB-2019 vaccine, which contains the S-Trimer protein with AS03 or CpG/Alum, induces strong body fluids and cellular immune responses to the new coronavirus, with high titular and antibody activity.
both adverbic vaccine formulations are well-to-do and can be further tested in clinical trials.